Recombinant Human IGFBP6 protein (Myc Tag, His Tag)

种属

Human

纯度

>90 %, SDS-PAGE

标签

Myc Tag, His Tag

生物活性

未测试

Cat no : Eg0087

Print datasheet

Synonyms

IBP 6, IBP6, IBP-6, IGF binding protein 6, IGF-binding protein 6



产品信息

纯度 >90 %, SDS-PAGE
内毒素 <1.0 EU/μg protein, LAL method
生物活性
Not tested
来源 HEK293-derived Human IGFBP6 protein Arg28-Gly240 (Accession# P24592) with a Myc tag and a His tag at the C-terminus.
基因ID 3489
蛋白编号 P24592
预测分子量 28.2 kDa
SDS-PAGE
组分 Lyophilized from sterile PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
复溶 Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
储存条件
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
运输条件 The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

背景信息

Insulin-like growth factor (IGF) binding protein (IGFBP6), a 240 amino acid protein, contains an IGFBP N-terminal domain and a thyroglobulin type-1 domain.It’s known for its identical protein binding activity and insulin-like growth factor II (IGF-II) binding activity. It plays a role in cell migration and positively regulates the stress-activated MAPK cascade. As a component of the insulin-like growth factor binary complex, IGFBP6 helps modulate the availability and activity of IGFs in the body. IGFBP6 has been implicated in obesity and serves as a biomarker for several conditions, including breast cancer, in situ carcinoma, leiomyoma, and neovascular inflammatory vitreoretinopathy. Research has shown that IGFBP6 can influence tumor progression and response to treatment in various cancer types, such as glioblastoma, ovarian cancer, and prostate cancer.

参考文献:

1.Liso, Arcangelo et al. International journal of molecular sciences vol. 23,8 (2022). 2.Piscazzi, Annamaria et al. Oncology letters vol. 23,6 (2022): 185. 3.Su, Meiming et al. Nature cardiovascular research vol. 4,2 (2025): 145-162.